MISSISSAUGA, ON, June 03, 2021 (CANADA NEWSWIRE) – KYE Pharmaceuticals Inc. (“KYE”) today announced a positive decision in their lawsuit in Canadian Federal Court challenging Health Canada’s approval of Medunik’s New Drug Submission (NDS) for Ruzurgi®.
June 03, 2021 at 3:10 PM EDT
MISSISSAUGA, ON, May 04, 2021 (CANADA NEWSWIRE) – CORZYNA™ (ranolazine extended-release tablets) has now been made commercially available and is in wholesalers across Canada after a positive expedited review by Health Canada.
May 04, 2021 at 8:30 AM EDT
CORZYNA™ is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies
January 5, 2021 at 9:00 AM EDT
MISSISSAUGA, ON, October 28, 2020 (CANADA NEWSWIRE) – KYE Pharmaceuticals Inc. (“KYE”), a private company headquartered in Mississauga, Ontario focused on bringing medicines that fulfill clinically significant unmet needs to the Canadian market, today announced an important milestone, FIRDAPSE® …
October 28, 2020 at 10:40 AM EDT
August 26, 2020 at 9:40 AM EDT
CORAL GABLES, Fla., Aug. 18, 2020 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular …
August 18, 2020 at 8:03 AM EDT
MONMOUTH JUNCTION, N.J. and MISSISSAUGA, Ontario, July 9, 2020 /CNW/ — Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and …
July 09, 2020, 07:30 ET